deltatrials
Completed PHASE2 NCT00002547

Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome

ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA

Sponsor: Barbara Ann Karmanos Cancer Institute

Conditions Leukemia Myelodysplastic Syndromes
Interventions allogeneic bone marrow transplantation busulfan cyclophosphamide cyclosporine cytarabine methotrexate syngeneic bone marrow transplantation
Updated 6 times since 2017 Last updated: Aug 6, 2012 Started: Aug 31, 1987 Primary completion: Oct 31, 2003 Completion: Oct 31, 2003

This PHASE2 trial investigates Leukemia and Myelodysplastic Syndromes and is currently completed. Barbara Ann Karmanos Cancer Institute leads this study, which shows 6 recorded versions since 1987 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Aug 1987

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Barbara Ann Karmanos Cancer Institute
  • National Cancer Institute (NCI)
Data source: Barbara Ann Karmanos Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Detroit, United States